| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 04/27/2006 | WO2006045010A2 Stilbenes and chalcones for the prevention and treatment of cardiovascular diseases |
| 04/27/2006 | WO2006045006A1 Antibiotic product formulation |
| 04/27/2006 | WO2006044968A2 Combination therapy for treating viral infections |
| 04/27/2006 | WO2006044961A1 Ppar-gamma modulatores |
| 04/27/2006 | WO2006044958A1 Pyrazolo [1,5-alpha] pyrimidinyl derivatives useful as corticotropin-releasing factor (crf) receptor antagonists |
| 04/27/2006 | WO2006044955A1 Phosphodiesterase 4 inhibitors |
| 04/27/2006 | WO2006044933A2 Compositions and methods for disruption of brca2-rad51 interaction |
| 04/27/2006 | WO2006044918A2 Compounds useful as substrates for enzymes that reverse nucleotidylylated peptide and protein modifications and methods for production and uses thereof |
| 04/27/2006 | WO2006044916A2 Use of na+/ k+-atpase inhibitors and antagonists thereof |
| 04/27/2006 | WO2006044903A1 HYDRATE OF N-METHYL-N-(3-{3-[2-THIENYLCARBONYL]-PYRAZOL-[1,5-α]- PYRAMIDIN-7-YL}PHENYL)ACETAMIDE AND PROCESSES AND METHODS RELATED THERETO |
| 04/27/2006 | WO2006044869A1 Synthesis of imidazooxazole and imidazothiazole inhibitors of p38 map kinase |
| 04/27/2006 | WO2006044861A2 Pharmaceutical mixture evaluation |
| 04/27/2006 | WO2006044860A2 Thiadiazole compounds and methods of use |
| 04/27/2006 | WO2006044856A2 Use of a2a adenosine receptor agonists |
| 04/27/2006 | WO2006044825A2 Mitotic kinesin inhibitors and methods of use thereof |
| 04/27/2006 | WO2006044823A2 Heteroaryl-substituted alkyne compounds and method of use |
| 04/27/2006 | WO2006044808A1 The use of nelfinavir as a radiation sensitizer |
| 04/27/2006 | WO2006044785A1 Process for making antimicrobial polymer articles |
| 04/27/2006 | WO2006044775A2 Preparation and use of biphenyl-4-yl-carbonylamino acid derivatives for the treatment of obesity |
| 04/27/2006 | WO2006044762A2 Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
| 04/27/2006 | WO2006044754A2 Process for preparing telmisartan |
| 04/27/2006 | WO2006044753A2 Chemical compounds |
| 04/27/2006 | WO2006044741A1 Use of (z)-2-cyano-3-hydroxy-but-2-enoic acid-(4'-trifluoromethylphenyl)-amide for treating inflammatory bowel disease |
| 04/27/2006 | WO2006044738A2 Methods and compositions for treatment of free radical injury |
| 04/27/2006 | WO2006044707A1 Chemical compounds |
| 04/27/2006 | WO2006044687A2 Kinase inhibitors |
| 04/27/2006 | WO2006044682A1 Compounds for nonsense suppression, and methods for their use |
| 04/27/2006 | WO2006044665A2 Neuroprotective spirostenol pharmaceutical compositions |
| 04/27/2006 | WO2006044657A2 Phosphate binder with reduced pill burden |
| 04/27/2006 | WO2006044648A1 Process for preparing telmisartan |
| 04/27/2006 | WO2006044645A2 Sulfamoyl benzamides and methods of their use |
| 04/27/2006 | WO2006044602A2 Diphenyl substituted alkanes as flap inhiibitors |
| 04/27/2006 | WO2006044600A1 Compositions containing piperacillin, tazobactam and a aminocarboxilic acid in a sodium lactate diluent |
| 04/27/2006 | WO2006044573A2 Reversible inhibitors of s-adenosyl-l-homocysteine hydrolase and uses thereof |
| 04/27/2006 | WO2006044556A2 Dual inhibitors of lipoxygenase for treating diabetes |
| 04/27/2006 | WO2006044528A1 Pyrazole derivatives as phosphodiesterase 4 inhibitors |
| 04/27/2006 | WO2006044527A1 Imidazole derivatives as vanilloid receptor ligands |
| 04/27/2006 | WO2006044524A1 Benzothieno’2,3-d! pyrimidine compounds as inhibitors of tyrosine kinase activities of the epidermal growth factor receptors (egfrs) for the treatment of hyperproliferative diseases |
| 04/27/2006 | WO2006044505A2 Compounds for nonsense suppression, and methods for their use |
| 04/27/2006 | WO2006044504A1 Cgrp receptor antagonists |
| 04/27/2006 | WO2006044497A2 Spiropiperidine compounds useful as beta-secretase inhibitors for the treatment of alzhermer’s disease |
| 04/27/2006 | WO2006044472A1 Carbamate compounds for use in treating neurodegenerative disorders |
| 04/27/2006 | WO2006044457A1 N-benzenesulfonyl substituted anilino-pyrimidine analogs |
| 04/27/2006 | WO2006044454A1 1-(hetero)aryl-3-amino-pyrollidine derivatives for use as mglur3 receptor antagonists |
| 04/27/2006 | WO2006044453A1 Analogs of 17-hydroxywortmannin as pi3k inhibitors |
| 04/27/2006 | WO2006044451A1 Treatment of osteoarthritis and dosing regimen for arzoxifene |
| 04/27/2006 | WO2006044449A2 Cgrp receptor antagonists |
| 04/27/2006 | WO2006044425A2 Ophthalmic compositions for treating ocular hypertension |
| 04/27/2006 | WO2006044415A2 Carboxylic acid peri - substituted bicyclics for occlusive artery disease |
| 04/27/2006 | WO2006044412A1 Novel b1 bradykinin receptor antagonists |
| 04/27/2006 | WO2006044405A1 Aryl sulfonamide peri-substituted bicyclics for occlusive artery disease |
| 04/27/2006 | WO2006044402A1 Furazano `3, 4-b ! pyrazynes and their use as anti-tumor agents |
| 04/27/2006 | WO2006044391A1 A method of reducing drug-induced adverse side effects in a patient |
| 04/27/2006 | WO2006044381A2 Cannabinergic lipid ligands |
| 04/27/2006 | WO2006044379A2 Novel curcumin analogues and uses thereof |
| 04/27/2006 | WO2006044362A2 N-sulfonylpiperidine cannabinoid receptor 1 antagonists |
| 04/27/2006 | WO2006044355A1 Triazoles and their use as bradykinin b1 receptor antagonists |
| 04/27/2006 | WO2006044342A2 Self-gelling alginate systems and uses thereof |
| 04/27/2006 | WO2006044333A2 Methods and materials for the inhibition of transplant rejection |
| 04/27/2006 | WO2006044297A1 Device for delivering an anti-microbial composition |
| 04/27/2006 | WO2006044293A2 Bicyclic compounds as selective melanin concentrating hormone receptor antagonists for the treatment of obesity and related disorders |
| 04/27/2006 | WO2006044232A1 Ophthalmic compositions for treating ocular hypertension |
| 04/27/2006 | WO2006044230A1 Water soluble prodrugs of cox-2 inhibitors |
| 04/27/2006 | WO2006044228A1 Histamine h3 receptor inhibitors, preparation and therapeutic uses |
| 04/27/2006 | WO2006044205A2 Methods and compositions for needleless delivery of macromolecules |
| 04/27/2006 | WO2006044176A1 Substituted benzopyrans as selective estrogen receptor-beta agonists |
| 04/27/2006 | WO2006044174A2 Aryl substituted 8-azabicyclo[3.2.1]octane compounds as ligands of the melanin concentrating hormone receptor |
| 04/27/2006 | WO2006044155A2 Ophthalmic compositions including lubricant, deturgescent agent, and glycosaminoglycan and methods of using the same |
| 04/27/2006 | WO2006044133A1 Active ketone inhibitors of tryptase |
| 04/27/2006 | WO2006044107A2 Method of treating human preeclampsia employing resibufagenin |
| 04/27/2006 | WO2006044101A2 Method and composition for supplementation of nutritional deficiencies in renal patients |
| 04/27/2006 | WO2006044090A2 Topical treatment with ngf and dha in damaged corneas |
| 04/27/2006 | WO2006044077A2 Controlled release composition with semi-permeable membrane and poloxamer flux enhancer |
| 04/27/2006 | WO2006044000A1 Sulfonamide pert-substituted bicyclics for occlusive artery disease |
| 04/27/2006 | WO2006043966A2 Methods for inducing apoptosis in adipocytes |
| 04/27/2006 | WO2006043965A1 Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods |
| 04/27/2006 | WO2006043846A1 Salt of montelukast with tert.-butylamine |
| 04/27/2006 | WO2006043839A1 Nitrobenzindoles and their use in cancer therapy |
| 04/27/2006 | WO2006043802A1 Anti-stress formula for human and veterinary use |
| 04/27/2006 | WO2006043800A1 Use of memantine for the prevention of neurotoxic reactions caused by antileukemic chemotherapy |
| 04/27/2006 | WO2006043783A1 Pharmaceutical compositions, comprising red ginseng acid polysaccharide and lentinus edodes, of preventing and treating cancer |
| 04/27/2006 | WO2006043722A1 Chimeric (double) decoy |
| 04/27/2006 | WO2006043710A1 Drug development target protein and target gene, and method of screening |
| 04/27/2006 | WO2006043691A1 Target protein and target gene in drug designing and screening method |
| 04/27/2006 | WO2006043671A1 TRANSCRIPTIONAL FACTOR Nrf2 ACTIVATOR AND FOOD HAVING THE FUNCTION OF THE SAME IMPARTED THERETO |
| 04/27/2006 | WO2006043655A1 Medicinal composition for inhalation |
| 04/27/2006 | WO2006043654A1 Acetonitrile derivative, pest control agent, and method of using the same |
| 04/27/2006 | WO2006043615A1 Use of immunesuppressant receptor |
| 04/27/2006 | WO2006043594A1 1,5-diheterocycle-1h-triazole derivative |
| 04/27/2006 | WO2006043532A1 Therapeutic agent for parkinson's disease |
| 04/27/2006 | WO2006043518A1 Drug for treating neurological disease |
| 04/27/2006 | WO2006043515A1 Pyrimidine-5-carboxylic acid derivative |
| 04/27/2006 | WO2006043510A1 Ester derivative and pharmaceutical use thereof |
| 04/27/2006 | WO2006043490A1 Pyrimidine derivative fused with nonaromatic ring |
| 04/27/2006 | WO2006043260A2 Orally effective cannabinoid analogs |
| 04/27/2006 | WO2006043172A1 Pharmaceutical compositions and methods for sub-tenon delivery |
| 04/27/2006 | WO2006043153A2 Use of zinc and copper chelators for the treatment of viral diseases |
| 04/27/2006 | WO2006043145A1 Inhibitors of hepatitis c virus protease, and compositions and treatments using the same |
| 04/27/2006 | WO2006043090A1 Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds |
| 04/27/2006 | WO2006043064A1 Piperidines and related compounds for treatment of alzheimer's disease |